Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 25, Issue 7, Pages 364-373Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2014.04.002
Keywords
mTORC2; c-Myc; metabolic reprogramming; epigenetics; drug resistance; glioblastoma
Categories
Funding
- National Institute for Neurological Diseases and Stroke [NS73831]
- National Cancer Institute [CA151819]
- Ben and Catherine Ivy Foundation
- Defeat GBM Research Collaborative
- National Brain Tumor Society
- Ziering Family Foundation
- National Foundation for Cancer Research
Ask authors/readers for more resources
Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to obtain the macromolecular precursors and energy needed for rapid tumor growth. Understanding how oncogenes coordinate altered signaling with metabolic reprogramming and global transcription may yield new insights into tumor pathogenesis, and provide a new landscape of promising drug targets, while yielding important clues into mechanisms of resistance to the signal transduction inhibitors currently in use. We review here the recently identified central regulatory role for mechanistic target of rapamycin complex 2 (mTORC2), a downstream effector of many cancer-causing mutations, in metabolic reprogramming and cancer drug resistance. We consider the impact of mTORC2-related metabolism on epigenetics and therapeutics, with a particular focus on the intractable malignant brain tumor, glioblastoma multiforme (GBM).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available